“The four principles of informed consent” almost always refers to bioethics principlism as applied to the consent process — the four prima facie principles of biomedical ethics developed by Tom Beauchamp and James Childress: autonomy, beneficence, non-maleficence, and justice. This is a different thing from the regulatory elements informed consent must contain under 45 CFR 46.116, which is covered separately in The Components of Informed Consent. This page is about the ethical reasoning underneath consent — why the process exists and what it’s meant to protect. That guide is about the checklist a consent form must satisfy to be compliant. Read this page for the “why,” that one for the “what’s legally required.”
It’s also worth distinguishing this framework from the Belmont Report’s three principles (respect for persons, beneficence, and justice), which is the framework most US research-ethics training actually cites for human subjects research. The two frameworks overlap heavily but are not identical, and mixing them up is a common source of confusion — see the comparison section below.
The four principles, and how each applies to consent specifically
Beauchamp and Childress introduced these four principles in Principles of Biomedical Ethics (first published 1979, now in multiple later editions) as a framework for reasoning through ethical dilemmas in medicine and biomedical research. None of the four is meant to be absolute or automatically override the others — in practice they function as “prima facie” duties that have to be weighed against each other in a given situation. Applied specifically to the consent process, each principle does distinct work.
1. Autonomy
Respect for autonomy means treating a prospective participant as capable of making their own decision about whether to take part in research, and structuring the consent process so that decision is genuinely theirs. In practice this is what informed consent operationalizes most directly: a person can’t exercise autonomous choice over something they don’t understand, so autonomy is the principle that generates the disclosure and comprehension requirements found in the regulatory elements (purpose, procedures, risks, benefits, alternatives) — the person needs accurate information before a choice can meaningfully be called their own. Autonomy is also the principle behind voluntariness safeguards: consent obtained under coercion, undue influence, or a power imbalance the participant can’t realistically resist isn’t autonomous, regardless of how complete the disclosure was.
2. Beneficence
Beneficence is the obligation to act in ways that benefit the participant and the broader goals of the research — promoting welfare, not merely avoiding harm. In the consent process, beneficence is why a researcher has to actually explain the potential benefits of participation (to the individual, where they exist, and to future patients or knowledge more broadly) rather than presenting only risks, and why an IRB weighs whether a study’s expected benefits justify asking anyone to accept its risks at all. Beneficence also underlies the researcher’s affirmative duty to design the study to maximize benefit and minimize unnecessary risk before a participant is ever asked to consent to it — consent isn’t a substitute for a well-designed, defensible study, it’s an additional safeguard on top of one.
3. Non-maleficence
Non-maleficence — primum non nocere, first do no harm — is often treated as bundled into beneficence in research-ethics contexts (this is exactly what the Belmont Report does; see below), but Beauchamp and Childress keep it analytically separate because it imposes a distinct kind of duty: an obligation not to actively harm someone, which is generally treated as a stronger obligation than the duty to actively benefit them. In consent terms, non-maleficence is the principle behind full and honest risk disclosure — a participant cannot avoid or accept a harm they were never told about — and behind an investigator’s ongoing duty to stop or modify a study if new information shows the risk profile has changed for the worse, independent of whether continuing might still produce a net benefit.
4. Justice
Justice concerns the fair distribution of the burdens and benefits of research — who is asked to bear the risks of participating, and who stands to benefit from what’s learned. For consent specifically, justice is the principle behind rules against exploiting vulnerable or easily-accessible populations (economically disadvantaged groups, institutionalized people, students of the person recruiting them) simply because they are convenient or unlikely to refuse, and behind ensuring that groups likely to benefit from a study’s results aren’t systematically excluded from having access to participate in it. It’s also the principle most directly engaged when consent is sought from populations with reduced capacity to consent for themselves — reflected in the additional protections in 45 CFR 46 Subparts B through D for pregnant women, prisoners, and children.
Four principles vs. three: how this differs from the Belmont Report
Researchers and IRB staff in the US are far more likely to have encountered the Belmont Report’s framework than Beauchamp and Childress’s directly, so it’s worth being precise about how they relate. The Belmont Report (1979) sets out three principles — respect for persons, beneficence, and justice — and names informed consent as the direct practical application of respect for persons specifically (its two other applications being risk/benefit assessment and equitable subject selection). Belmont folds non-maleficence into its beneficence principle rather than treating it as a fourth, separate principle. Beauchamp and Childress’s four-principle framework, published the same year, keeps non-maleficence distinct. Neither framework is “more correct” — they’re two related articulations of the same underlying bioethics tradition, and both pre-date and inform the Common Rule’s regulatory requirements. If your institution’s human-subjects training cites “three principles,” it’s very likely drawing on Belmont; if a bioethics or philosophy source cites “four principles,” it’s very likely drawing on Beauchamp and Childress.
From principle to practice: how these connect to the required elements
The four principles explain why informed consent has to contain what it contains — they don’t themselves specify a checklist. The specific, auditable requirements a consent process and consent document must satisfy are set out in regulation, most directly 45 CFR 46.116 for research subject to the Common Rule (and the closely parallel 21 CFR 50.25 for FDA-regulated research). The Components of Informed Consent walks through those required elements one by one. Roughly:
- Disclosure of purpose, procedures, risks, benefits, and alternatives — traces back to autonomy (comprehension) and non-maleficence (honest risk disclosure).
- Statement of expected benefits — traces back to beneficence.
- Voluntary participation and the right to withdraw without penalty — traces back to autonomy.
- Fair, non-coercive recruitment and equitable selection of who is asked to participate — traces back to justice.
An IRB reviewing a protocol under the Common Rule is, in effect, checking that a specific document and process satisfy these underlying principles — the regulation is the operationalized, auditable form of the ethics, not a separate requirement layered on top of it. For how Good Clinical Practice frames this same relationship internationally, see What Is Good Clinical Practice (GCP)?, which notes that ICH E6 explicitly grounds trial conduct in ethical principles consistent with the Declaration of Helsinki.
Where the principles create tension in practice
The four principles don’t always point the same direction, and part of what an IRB or investigator has to reason through is how to weigh them against each other in a specific case. A few recurring tensions:
- Autonomy vs. beneficence. A participant may want to enroll in a study a researcher believes offers them little realistic benefit, or decline a study that offers a genuinely favorable risk/benefit profile. Respecting autonomy means honoring that choice either way, even where it looks like it cuts against the participant’s own welfare as the researcher sees it.
- Therapeutic misconception. Participants — particularly patients enrolling in a trial through their own treating clinician — can conflate research participation with personalized medical care, overestimating the direct benefit to them specifically. This is a beneficence-adjacent risk to genuine autonomous consent: a person can’t exercise real autonomy over a decision they’ve misunderstood in this specific way, which is why consent processes are expected to actively correct for it, not just disclose information and assume it lands correctly.
- Justice vs. practical access. Restricting a study to populations easy to recruit from can conflict with justice’s concern that the benefits of research findings should be available to the same populations that bore the burden of participating in generating them.
Frequently asked questions
Are there really only four principles, or is it sometimes three?
Both framings exist and are legitimate — see the comparison section above. Beauchamp and Childress’s bioethics framework has four (autonomy, beneficence, non-maleficence, justice); the Belmont Report’s framework, which most US research-ethics training is built around, has three (respect for persons, beneficence, justice), with non-maleficence treated as part of beneficence rather than separated out.
Is this the same as the required elements of informed consent?
No. The four principles are the ethical reasoning behind why informed consent exists and what it protects. The required elements are the specific, regulated content a consent process and document must actually contain (45 CFR 46.116 in the US). See The Components of Informed Consent for the regulatory checklist.
Which principle is informed consent “based on” most directly?
Autonomy is generally treated as the principle informed consent most directly operationalizes — it’s the mechanism by which respect for a person’s capacity to make their own decision gets put into practice. But beneficence, non-maleficence, and justice all shape specific requirements within the consent process itself, as described above; consent isn’t reducible to autonomy alone.
Do these principles apply outside biomedical research?
Yes. Beauchamp and Childress developed the framework for biomedical ethics broadly, including clinical care as well as research, and it is widely taught in medical, nursing, and allied-health ethics curricula, not only in the research-consent context. This page focuses specifically on how the four principles bear on the research informed consent process.
For the practical mechanics of building and delivering a compliant consent process, see Informed Consent in Research: What It Requires and How It Works and When Should Informed Consent Be Obtained?. For the underlying vocabulary term, see Informed consent.
